JP2023502503A5 - - Google Patents
Info
- Publication number
- JP2023502503A5 JP2023502503A5 JP2022529859A JP2022529859A JP2023502503A5 JP 2023502503 A5 JP2023502503 A5 JP 2023502503A5 JP 2022529859 A JP2022529859 A JP 2022529859A JP 2022529859 A JP2022529859 A JP 2022529859A JP 2023502503 A5 JP2023502503 A5 JP 2023502503A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- domain
- multicistronic
- vector
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025181523A JP2026035586A (ja) | 2016-09-02 | 2025-10-28 | ＤｕｏＣＡＲによりがんを処置するための組成物および方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382791P | 2016-09-02 | 2016-09-02 | |
| US16/692,957 US11208455B2 (en) | 2016-09-02 | 2019-11-22 | Compositions and methods for treating cancer with DuoCARs |
| US16/692,957 | 2019-11-22 | ||
| PCT/US2020/061623 WO2021102337A1 (en) | 2016-09-02 | 2020-11-20 | Compositions and methods for treating cancer with duocars |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025181523A Division JP2026035586A (ja) | 2016-09-02 | 2025-10-28 | ＤｕｏＣＡＲによりがんを処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023502503A JP2023502503A (ja) | 2023-01-24 |
| JP2023502503A5 true JP2023502503A5 (https=) | 2023-11-28 |
| JP7766595B2 JP7766595B2 (ja) | 2025-11-10 |
Family
ID=60022150
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512234A Active JP7160482B2 (ja) | 2016-09-02 | 2017-09-01 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2021514984A Active JP7423610B2 (ja) | 2016-09-02 | 2019-09-18 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2022529859A Active JP7766595B2 (ja) | 2016-09-02 | 2020-11-20 | ＤｕｏＣＡＲによりがんを処置するための組成物および方法 |
| JP2022100960A Active JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2024005142A Pending JP2024054133A (ja) | 2016-09-02 | 2024-01-17 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2024110705A Active JP7849417B2 (ja) | 2016-09-02 | 2024-07-10 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2025181523A Pending JP2026035586A (ja) | 2016-09-02 | 2025-10-28 | ＤｕｏＣＡＲによりがんを処置するための組成物および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512234A Active JP7160482B2 (ja) | 2016-09-02 | 2017-09-01 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2021514984A Active JP7423610B2 (ja) | 2016-09-02 | 2019-09-18 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022100960A Active JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2024005142A Pending JP2024054133A (ja) | 2016-09-02 | 2024-01-17 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2024110705A Active JP7849417B2 (ja) | 2016-09-02 | 2024-07-10 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2025181523A Pending JP2026035586A (ja) | 2016-09-02 | 2025-10-28 | ＤｕｏＣＡＲによりがんを処置するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (9) | US11453712B2 (https=) |
| EP (4) | EP3507304B1 (https=) |
| JP (7) | JP7160482B2 (https=) |
| CN (5) | CN109843922B (https=) |
| AU (4) | AU2017321894B2 (https=) |
| CA (3) | CA3035615A1 (https=) |
| ES (1) | ES2981703T3 (https=) |
| WO (3) | WO2018045325A1 (https=) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201600853UA (en) | 2013-08-05 | 2016-03-30 | Twist Bioscience Corp | De novo synthesized gene libraries |
| CA2932424C (en) * | 2013-12-06 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| FI3240805T3 (fi) | 2014-12-15 | 2025-02-17 | Univ California | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori |
| US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| EP3350314A4 (en) | 2015-09-18 | 2019-02-06 | Twist Bioscience Corporation | OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF |
| KR102794025B1 (ko) | 2015-09-22 | 2025-04-09 | 트위스트 바이오사이언스 코포레이션 | 핵산 합성을 위한 가요성 기판 |
| PL3368571T3 (pl) | 2015-10-30 | 2023-05-02 | The Regents Of The University Of California | Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania |
| EP3184548A1 (en) | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
| ES2981703T3 (es) * | 2016-09-02 | 2024-10-10 | Lentigen Tech Inc | Composiciones y métodos para tratar cáncer con DuoCars |
| US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
| EP4556433A3 (en) | 2017-02-22 | 2025-08-06 | Twist Bioscience Corporation | Nucleic acid based data storage |
| CA3057838A1 (en) * | 2017-03-24 | 2018-09-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd33 immunotherapy |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| WO2018231872A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| WO2019028051A1 (en) * | 2017-07-31 | 2019-02-07 | Lentigen Technology, Inc. | COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY |
| US11407837B2 (en) | 2017-09-11 | 2022-08-09 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
| US10543263B2 (en) * | 2017-10-16 | 2020-01-28 | Lentigen Technology Inc. | Compositions and methods for treating cancer with anti-CD22 immunotherapy |
| CN111565834B (zh) | 2017-10-20 | 2022-08-26 | 特韦斯特生物科学公司 | 用于多核苷酸合成的加热的纳米孔 |
| GB201719646D0 (en) * | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
| KR102804057B1 (ko) | 2018-01-04 | 2025-05-07 | 트위스트 바이오사이언스 코포레이션 | Dna 기반 디지털 정보 저장 |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| US20210254068A1 (en) * | 2018-06-19 | 2021-08-19 | Regents Of The University Of Minnesota | Genome engineering primary monocytes |
| JP7611705B2 (ja) * | 2018-06-22 | 2025-01-10 | ザ ジェネラル ホスピタル コーポレイション | Ｃｄ３７及びｃｄ１９を標的とするキメラ抗原受容体 |
| AU2019299439C1 (en) * | 2018-07-03 | 2025-06-26 | Sotio Biotech, Inc. | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| EP3829312A4 (en) * | 2018-08-04 | 2022-07-06 | Abcyte Therapeutics Inc. | MULTIFUNCTIONAL AND MULTI-TARGETING CAR SYSTEM AND METHODS OF USE |
| US11242389B2 (en) | 2018-09-26 | 2022-02-08 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy |
| JP7546554B2 (ja) * | 2018-09-26 | 2024-09-06 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法 |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| WO2020139871A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| CN109485734B (zh) * | 2018-12-30 | 2020-05-12 | 广州百暨基因科技有限公司 | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 |
| EP3908613A4 (en) * | 2019-01-07 | 2022-10-19 | Celluris Participações Ltda. | BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA |
| SG11202108618VA (en) * | 2019-02-15 | 2021-09-29 | Advanced Cell Diagnostics Inc | Methods for multiplex detection of nucleic acids by in situ hybridization |
| AU2020226401A1 (en) * | 2019-02-18 | 2021-10-14 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| CN113766930B (zh) | 2019-02-26 | 2025-07-22 | 特韦斯特生物科学公司 | Glp1受体的变异核酸文库 |
| JP2022522668A (ja) | 2019-02-26 | 2022-04-20 | ツイスト バイオサイエンス コーポレーション | 抗体を最適化するための変異体核酸ライブラリ |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| CN113924103B (zh) * | 2019-03-06 | 2025-02-14 | 莱蒂恩技术公司 | 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法 |
| US20220145325A1 (en) * | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| WO2020210719A1 (en) * | 2019-04-10 | 2020-10-15 | Elevatebio Management, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| EP3965897A4 (en) * | 2019-05-07 | 2023-01-04 | The Board of Trustees of the Leland Stanford Junior University | CHEMERA ANTIGEN RECEPTORS TARGETING GLYPICAN-2 |
| AU2020275049A1 (en) * | 2019-05-16 | 2022-01-06 | Nanjing Legend Biotech Co., Ltd. | Engineered immune cells comprsing a recognition molecule |
| EP3980453A4 (en) * | 2019-06-07 | 2023-07-05 | The Trustees of the University of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| WO2020252110A1 (en) * | 2019-06-14 | 2020-12-17 | Bluebird Bio, Inc. | Compositions and methods for treating cancer |
| US11332738B2 (en) | 2019-06-21 | 2022-05-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| EP4001312A4 (en) * | 2019-07-18 | 2023-08-16 | JW Bioscience | Antibody specifically binding to wrs protein, and use thereof |
| CN112442509A (zh) * | 2019-08-29 | 2021-03-05 | 爱博赛特生物治疗公司 | Cd19-cd20双特异性和双通道car-t及其使用方法 |
| JP2022548783A (ja) | 2019-09-23 | 2022-11-21 | ツイスト バイオサイエンス コーポレーション | 単一ドメイン抗体のバリアント核酸ライブラリー |
| EP4034566A4 (en) | 2019-09-23 | 2024-01-24 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CRTH2 |
| US12497453B2 (en) * | 2019-09-27 | 2025-12-16 | Nanjing Immunophage Biotech Co., Ltd. | ROR1 specific chimeric antigen receptors and their therapeutic applications |
| WO2021092593A1 (en) * | 2019-11-08 | 2021-05-14 | The University Of North Carolina At Chapel Hill | Use of agonists to augment car t function in solid tumors |
| CN112812182B (zh) * | 2019-11-15 | 2023-01-06 | 深圳宾德生物技术有限公司 | 一种靶向fgfr4的单链抗体、嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN112813030A (zh) * | 2019-11-15 | 2021-05-18 | 深圳宾德生物技术有限公司 | 一种靶向fgfr4和dr5的嵌合抗原受体t细胞及其制备方法和应用 |
| EP4065157A1 (en) * | 2019-11-26 | 2022-10-05 | Novartis AG | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| US12595311B2 (en) | 2020-03-02 | 2026-04-07 | The Regents Of The University Of California | Chimeric antigen receptors and related methods and compositions for the treatment of cancer |
| US11497770B2 (en) | 2020-06-22 | 2022-11-15 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy |
| US20230256064A1 (en) * | 2020-07-23 | 2023-08-17 | Medytox Inc. | Cancer therapeutic agent |
| EP4204460A4 (en) | 2020-08-26 | 2024-09-25 | Twist Bioscience Corporation | METHODS AND COMPOSITIONS RELATING TO GLP1R VARIANTS |
| EP4210832A1 (en) * | 2020-09-14 | 2023-07-19 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
| JP2023549079A (ja) * | 2020-10-30 | 2023-11-22 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 二重標的化キメラ抗原受容体 |
| AU2021372997A1 (en) * | 2020-11-05 | 2023-06-22 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
| CN114539421B (zh) * | 2020-11-18 | 2024-03-12 | 复旦大学 | 以HIV-1 gp120与CD20为双靶点的CAR-T细胞制备方法及其应用 |
| TW202307210A (zh) * | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| CA3228773A1 (en) * | 2021-08-12 | 2023-02-16 | Gaurav KHARYA | Chimeric antigen receptors (car) for b cell malignancies |
| IL311665A (en) * | 2021-10-01 | 2024-05-01 | Univ Texas | Antibody loaded immune cells and methods for use in cancer treatment |
| WO2023129929A1 (en) | 2021-12-30 | 2023-07-06 | Tr1X, Inc. | Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof |
| CN119923410A (zh) * | 2022-07-28 | 2025-05-02 | 莱蒂恩技术公司 | 用于治疗实体瘤的嵌合抗原受体治疗 |
| CA3263303A1 (en) * | 2022-08-04 | 2024-02-08 | Lyell Immunopharma, Inc. | METHODS FOR MANUFACTUREING CHIMERICAL ANTIGENIC RECEPTOR T LYMPHOCYTES |
| EP4331546A1 (en) | 2022-08-31 | 2024-03-06 | HyPro Innovation GmbH | Absorbent thermal effect pad |
| WO2024220598A2 (en) * | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| WO2025051339A1 (en) | 2023-09-05 | 2025-03-13 | Tiber Biotech Srl | SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR |
| EP4520346A1 (en) | 2023-09-06 | 2025-03-12 | Gyncentrum Sp. z o.o. | Cells, methods and systems for use in the treatment of a cancer with dual-car-t |
| US20250121007A1 (en) * | 2023-10-13 | 2025-04-17 | GenCART, Inc. | Compositions for the treatment of cancer |
| WO2026015450A1 (en) | 2024-07-06 | 2026-01-15 | Tr1X, Inc. | Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof |
| WO2026078200A1 (en) * | 2024-10-11 | 2026-04-16 | Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern | An improved system for antigen targeting |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US498298A (en) | 1893-05-30 | Range | ||
| US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
| US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| DE69311538D1 (de) | 1992-03-12 | 1997-07-17 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| WO1998036765A1 (en) | 1997-02-25 | 1998-08-27 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| BRPI0412007A (pt) * | 2003-06-27 | 2006-08-15 | Bioren Inc | mutagênese look-through |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス， インコーポレイテッド | Ｄｒ５リガンド薬物結合体 |
| CA2776143A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US20110212088A1 (en) | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| BR112014029417B1 (pt) | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| RU2658485C2 (ru) * | 2012-10-24 | 2018-06-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы м971 |
| US9217807B2 (en) | 2013-07-23 | 2015-12-22 | Schlumberger Technology Corporation | Systems and methods for identifying sanding in production wells using time-lapse sonic data |
| MX373687B (es) | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| CA2932424C (en) | 2013-12-06 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| ES2836743T3 (es) | 2014-06-02 | 2021-06-28 | Us Health | Receptores de antígeno quiméricos que seleccionan como diana CD-19 |
| TWI719942B (zh) * | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| EP3018200A1 (en) * | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
| FI3240805T3 (fi) | 2014-12-15 | 2025-02-17 | Univ California | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori |
| PL3560953T3 (pl) | 2014-12-24 | 2024-05-13 | Autolus Limited | Komórka |
| WO2016172537A1 (en) | 2015-04-23 | 2016-10-27 | The Trustees Of The University Of Pennsylvania | Compositions to disrupt protein kinase a anchoring and uses thereof |
| HRP20200439T1 (hr) * | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| US20190119635A1 (en) * | 2015-05-05 | 2019-04-25 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
| EP4286511A3 (en) * | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| US11655452B2 (en) * | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| CN107709356A (zh) * | 2015-06-26 | 2018-02-16 | 南加利福尼亚大学 | 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞 |
| JP6821688B2 (ja) | 2015-10-09 | 2021-01-27 | ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | キメラ抗原受容体および使用方法 |
| CN105331586B (zh) | 2015-11-20 | 2020-09-15 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
| EP3426273B1 (en) | 2016-03-11 | 2021-04-21 | Harmonic Pharma | Sublingual compositions comprising natural extracts and uses thereof |
| ES2981703T3 (es) | 2016-09-02 | 2024-10-10 | Lentigen Tech Inc | Composiciones y métodos para tratar cáncer con DuoCars |
| CA3057838A1 (en) | 2017-03-24 | 2018-09-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd33 immunotherapy |
| CN108220247A (zh) * | 2018-03-20 | 2018-06-29 | 杭州史迪姆生物科技有限公司 | 一种双car-t细胞及其制备方法和应用 |
-
2017
- 2017-09-01 ES ES17780539T patent/ES2981703T3/es active Active
- 2017-09-01 EP EP17780539.7A patent/EP3507304B1/en active Active
- 2017-09-01 WO PCT/US2017/049923 patent/WO2018045325A1/en not_active Ceased
- 2017-09-01 CN CN201780061243.8A patent/CN109843922B/zh active Active
- 2017-09-01 JP JP2019512234A patent/JP7160482B2/ja active Active
- 2017-09-01 EP EP23184693.2A patent/EP4282969A3/en active Pending
- 2017-09-01 US US16/078,269 patent/US11453712B2/en active Active
- 2017-09-01 AU AU2017321894A patent/AU2017321894B2/en active Active
- 2017-09-01 CN CN202311164481.5A patent/CN117298260A/zh active Pending
- 2017-09-01 CA CA3035615A patent/CA3035615A1/en active Pending
-
2018
- 2018-09-18 US US16/134,735 patent/US10689431B2/en active Active
-
2019
- 2019-09-18 JP JP2021514984A patent/JP7423610B2/ja active Active
- 2019-09-18 CN CN201980072801.XA patent/CN113382745B/zh active Active
- 2019-09-18 EP EP19790096.2A patent/EP3852789A2/en active Pending
- 2019-09-18 AU AU2019342730A patent/AU2019342730A1/en active Pending
- 2019-09-18 WO PCT/US2019/051734 patent/WO2020061194A2/en not_active Ceased
- 2019-09-18 CA CA3113194A patent/CA3113194A1/en active Pending
- 2019-09-18 CN CN202410358222.4A patent/CN118370808A/zh active Pending
- 2019-11-22 US US16/692,957 patent/US11208455B2/en active Active
-
2020
- 2020-06-22 US US16/907,713 patent/US11802142B2/en active Active
- 2020-11-20 CA CA3158878A patent/CA3158878A1/en active Pending
- 2020-11-20 WO PCT/US2020/061623 patent/WO2021102337A1/en not_active Ceased
- 2020-11-20 AU AU2020386636A patent/AU2020386636A1/en active Pending
- 2020-11-20 EP EP20825051.4A patent/EP4061407A1/en active Pending
- 2020-11-20 CN CN202080092701.6A patent/CN115768462A/zh active Pending
- 2020-11-20 JP JP2022529859A patent/JP7766595B2/ja active Active
-
2021
- 2021-12-02 US US17/540,377 patent/US12365718B2/en active Active
-
2022
- 2022-05-25 US US17/752,966 patent/US20220281946A1/en active Pending
- 2022-06-23 JP JP2022100960A patent/JP7522156B2/ja active Active
-
2023
- 2023-07-06 US US18/347,644 patent/US20240025962A1/en active Pending
- 2023-09-12 US US18/465,233 patent/US20240043497A1/en active Pending
-
2024
- 2024-01-17 JP JP2024005142A patent/JP2024054133A/ja active Pending
- 2024-07-10 JP JP2024110705A patent/JP7849417B2/ja active Active
-
2025
- 2025-01-24 AU AU2025200478A patent/AU2025200478A1/en active Pending
- 2025-06-17 US US19/240,490 patent/US20250367291A1/en active Pending
- 2025-10-28 JP JP2025181523A patent/JP2026035586A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023502503A5 (https=) | ||
| JP2019534246A5 (https=) | ||
| US20250034244A1 (en) | Bicistronic chimeric antigen receptors and their uses | |
| JP2022524507A5 (https=) | ||
| JP7179041B2 (ja) | 三官能性ｔ細胞－抗原カプラ及び方法並びにこれらの使用 | |
| JP2025107475A (ja) | 抗ｔｒｂｃ１抗原結合ドメイン | |
| CN113227379A (zh) | 多功能多靶向嵌合抗原受体（car）系统及其使用方法 | |
| JP2022001067A (ja) | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 | |
| US20180371052A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
| EP3765514A1 (en) | Anti-cd33 chimeric antigen receptors and their uses | |
| CA3093705A1 (en) | Anti-gucy2c chimeric antigen receptor compositions and methods | |
| JP7662588B2 (ja) | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 | |
| JP2021502070A5 (https=) | ||
| JP2022502043A5 (https=) | ||
| CN118420783A (zh) | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 | |
| EP3331920A1 (en) | Bispecific car t-cells for solid tumor targeting | |
| CN104853766A (zh) | 用于免疫疗法的组合物和方法 | |
| CN114364801A (zh) | 用于用抗bcma免疫治疗来治疗癌症的组合物和方法 | |
| WO2022218226A1 (zh) | 工程化免疫细胞及其用途 | |
| Chmielewski et al. | T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term | |
| US20250018040A1 (en) | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors | |
| JP2023548974A (ja) | Ｔ細胞抗原カプラを含む細胞及びその使用 | |
| WO2017179015A1 (en) | Compositions for the treatment of cancer | |
| US20210079111A1 (en) | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof | |
| US20230302051A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs), TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF |